立体定向体部放疗治疗局部晚期胰腺癌:前瞻性试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入23项前瞻性研究、901例局部晚期不可切除胰腺癌患者,评估确定性SBRT(最多6次分割)的疗效与毒性。汇总12个月和24个月局部控制率分别为82%和70%,12个月OS为63%,≥3级毒性风险仅2%。分次≥5次、较高BED10、包含选择性临床靶区及后续手术与部分疗效改善相关。
要点
- SBRT治疗局部晚期胰腺癌的12个月和24个月局部控制率分别为82%和70%。
- ≥3级毒性汇总风险为2%,5级毒性风险为0.2%,主要为消化道出血。
- 分次≥5次、较高BED10、包含选择性临床靶区及手术与部分生存或控制改善相关。
核心结论
- 现代放疗技术可安全实施高剂量SBRT,局部控制优异且持久,≥3级治疗相关毒性发生率低。
研究设计与样本
- 系统综述与荟萃分析,纳入23项前瞻性确定性SBRT(最多6次分割)治疗局部晚期不可切除胰腺癌的研究,共901例患者,采用随机效应模型及元回归分析。
主要发现
- 汇总12个月和24个月局部控制率分别为82%和70%。
- 12个月无进展生存率和总生存率分别为35%和63%,24个月分别为15%和28%。
- 任何3-4级毒性汇总风险为2%,5级毒性风险为0.2%(7例事件),主要为消化道出血。
- 单变量元回归显示,SBRT分次≥5次与12个月局部控制和总生存改善相关。
- 包含选择性临床靶区与24个月无进展生存和总生存改善相关,较高BED10与24个月局部控制和总生存改善相关。
关键数值与推荐
- 多数研究(21项,91.3%)在SBRT前使用全身治疗,中位剂量为40 Gy/5次(范围24-50 Gy/3-6次)。
- 手术与12个月和24个月总生存及12个月无进展生存改善相关。
- 未发现3-4级或5级毒性的预测因素。
临床怎么用
- 对于局部晚期不可切除胰腺癌,SBRT可作为安全且局部控制率高的确定性放疗选择。
- 采用分次≥5次、较高BED10及包含选择性临床靶区的方案可能与更好的生存或局部控制相关。
局限性
- 本文为系统综述与荟萃分析,纳入研究间存在异质性,元回归结果需谨慎解读。
- 未报告3-4级或5级毒性的预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Modern technology has facilitated dose-escalated stereotactic body radiation therapy (SBRT) through real-time soft-tissue delineation and adaptive radiation therapy for locally advanced/unresectable pancreatic cancer (LAPC). The current study examined published prospective trials in SBRT for LAPC to inform clinical decision-making with support from the International Stereotactic Radiosurgery Society. METHODS AND MATERIALS: A systematic review and meta-analysis was conducted of all prospective trials in definitive SBRT (up to 6 fractions) for LAPC. Random-effects meta-analysis was performed, and metaregression was used to assess the effect of covariates on outcomes of interest, including local control (LC), progression-free survival (PFS), overall survival (OS), and toxicities. RESULTS: A total of 23 prospective studies were identified, including 901 patients. Most studies (n = 21, 91.3%) used systemic therapy before SBRT and delivered a median dose of 40 Gy in 5 fractions (range, 24-50 Gy in 3-6 fractions). The pooled 12- and 24-month LC estimate was 82% and 70%, respectively; 12-month PFS and OS rates were 35% and 63%, respectively; and 24-month PFS and OS rates were 15% and 28%, respectively. On univariable metaregression, SBRT with ≥5 fractions was associated with improved 12-month LC and OS. Inclusion of an elective clinical target volume was associated with improved 24-month PFS and OS. A higher biologically effective dose (BED10) was associated with improved 24-month LC and OS. Surgery was associated with improved 12- and 24-month OS and 12-month PFS. The pooled estimate for risk of any grade 3-4 toxicities was 2%, and that of grade 5 toxicities was 0.2% (7 events), mostly gastrointestinal bleeding. There were no predictors of grade 3-4 or 5 toxicities. CONCLUSIONS: Modern radiation therapy techniques allow safe delivery of high radiation doses for LAPC. SBRT provides excellent and durable LC with low rates of treatment-related grades ≥3 toxicities.
引用
- Zeng KL, Louie AV, Kotecha R, et al. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis of Prospective Trials. Pract Radiat Oncol. 2026. PMID: 42103102. doi:10.1016/j.prro.2026.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。